packageRegdanvimab

regdanvimab

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Regdanvimab is a monoclonal antibody that was used to treat COVID-19 infection. It was approved in the European Union but has since been withdrawn from use there.

Summary written by glm-5.3-flash from Wikidata Q105687595 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:regdanvimab
ATC codes:J06BD06
DrugBank:DB16405
Wikidata:Q105687595

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown